A Single Arm Multi-center Study Investigating the at Home Administration of Trastuzumab Subcutaneous Vial for the Treatment of Patients With HER2-positive Early Breast Cancer
Phase of Trial: Phase III
Latest Information Update: 19 Sep 2019
Price : $35 *
At a glance
- Drugs Trastuzumab (Primary) ; Trastuzumab (Primary)
- Indications Adenocarcinoma; Early breast cancer; Male breast cancer
- Focus Adverse reactions; Registrational
- Acronyms BELIS; Umbrella_BELIS
- Sponsors Roche
- 23 Nov 2018 Status changed from active, no longer recruiting to completed.
- 11 Oct 2016 Interim safety results of this and other four phase 3 studies presented at the 41st European Society for Medical Oncology Congress (2016).
- 02 Nov 2015 Planned End Date changed from 1 Aug 2017 to 1 Sep 2017 as per ClinicalTrials.gov record.